Distinct long-term regulation of glycerol and non-esterified fatty acid release by insulin and TNF-alpha in 3T3-L1 adipocytes

Diabetologia. 2001 Jan;44(1):55-62. doi: 10.1007/s001250051580.

Abstract

Aims/hypothesis: Adipose tissue lipolysis plays a central part in total body fuel metabolism. Our study was to assess the long-term regulation of glycerol and non-esterified fatty acid (NEFA) release by insulin or TNF-alpha.

Methods: Fully differentiated 3T3-L1 adipocytes were exposed for up to 22 h to insulin or TNF-alpha.

Results: Long-term insulin treatment resulted in increased basal glycerol release, reaching sixfold at 22 h with 1 nmol/l insulin. Partial inhibition was observed by pharmacologically inhibiting phosphatidylinositol 3-kinase or the mitogen-activated kinase kinase--extracellular signal-regulated kinase cascades. This represented 50-60% of the response induced by 1 nmol/l TNF-alpha and approximately 40 % of the glycerol release maximally stimulated by isoproterenol (1 micromol/l, 30 min). The cellular mechanism seemed to be distinct from that of TNF-alpha: First, glycerol release in response to long-term insulin was progressive with time and did not display a lag-time characteristic of the effect of TNF-alpha. Second, pretreatment and co-treatment of the cells with troglitazone greatly inhibited TNF-alpha-induced glycerol release (128.5 +/- 10.2 to 35.4 +/- 2.1 nmol/mg protein per h) but not the effect of insulin, which was exaggerated. Third, hormone-sensitive lipase protein content was decreased (45 %) by TNF-alpha but not following long-term insulin. Finally, TNF-alpha was associated with NEFA release to the medium, whereas long-term insulin treatment was not. Moreover, glycerol release during isoproterenol-stimulated lipolysis was additive to the effect of long-term insulin, whereas NEFA release was inhibited by nearly 90 %. CONCLUSIONS INTERPRETATION: Contradictory to its short-term inhibitory effect, long-term insulin stimulates glycerol release with concomitant stimulation of NEFA re-esterification.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3T3 Cells
  • Adipocytes / drug effects*
  • Adipocytes / metabolism*
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Blood Glucose / metabolism
  • Cell Membrane / chemistry
  • Chromones / pharmacology
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Fatty Acids, Nonesterified / metabolism*
  • Flavonoids / pharmacology
  • Glucose Transporter Type 4
  • Glycerol / metabolism*
  • Insulin / administration & dosage
  • Insulin / pharmacology*
  • Insulin Receptor Substrate Proteins
  • Kinetics
  • Lipolysis / drug effects
  • Mice
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Monosaccharide Transport Proteins / analysis
  • Morpholines / pharmacology
  • Muscle Proteins*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoproteins / analysis
  • Thiazoles / pharmacology
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Adrenergic beta-Agonists
  • Blood Glucose
  • Chromones
  • Enzyme Inhibitors
  • Fatty Acids, Nonesterified
  • Flavonoids
  • Glucose Transporter Type 4
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Irs1 protein, mouse
  • Monosaccharide Transport Proteins
  • Morpholines
  • Muscle Proteins
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoproteins
  • Slc2a4 protein, mouse
  • Thiazoles
  • Tumor Necrosis Factor-alpha
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Mitogen-Activated Protein Kinases
  • Glycerol
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one